On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $223 billion and an impressive 82% gross profit margin according to InvestingPro, announced today that ...

Also Read: FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients The approval is based on results from the DESTINY-Breast06 Phase 3 trial.

This new indication builds on the established role of Imfinzi in unresectable disease and underscores our commitment to transforming care in the early stages of lung cancer where there is the greatest ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...